# A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures

> **NCT01199757** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 540 (actual)

## Conditions studied

- Rhinitis, Allergic, Perennial

## Interventions

- **DRUG:** Fluticasone furoate
- **DRUG:** mometasone furoate
- **DRUG:** fluticasone propionate

## Key facts

- **NCT ID:** NCT01199757
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-10
- **Primary completion:** 2009-08-01
- **Final completion:** 2009-08-01
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2017-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01199757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01199757, "A Comparison of Patients on AVAMYS ® Versus NASONEX (A Trade Mark of Schering Corporation) and FLIXONASE ® on Key Health Outcome Measures". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01199757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*